Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Wednesday, September 21, 2022
Findings from an exploratory analysis of the phase III POSEIDON trial presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA59) suggest the overall survival benefit associated with chemotherapy plus durvalumab and tremelimumab may be durable and long term. Initial study analysis indicated improvements in progression-free and overall survival in patients who received the combination treatment versus chemotherapy alone.
“These data support the use of this regimen as a [first-line] treatment option for [patients with metastatic non–small cell lung cancer], including harder-to-treat mutational subgroups such as STK11, KEAP1, or KRAS,” concluded Melissa L. Johnson, MD, of the Sarah Cannon Research Institute, Nashville, and colleagues.
The study included patients who were randomly assigned to receive either chemotherapy (n = 337), chemotherapy plus durvalumab (n = 338), or chemotherapy plus durvalumab and tremelimumab (n = 338). At a median follow-up of 46.5 months, the 3-year overall survival was longer for patients who received the triplet regimen (25%) than for those who received chemotherapy alone (13.6%). A combination treatment of chemotherapy plus durvalumab was also associated with numerically improved overall survival versus chemotherapy.
Patients with nonsquamous disease were more likely to experience superior overall survival after receiving the triplet treatment versus chemotherapy alone. However, chemotherapy plus durvalumab and tremelimumab was also associated with improved overall survival versus chemotherapy in patients with nonsquamous disease who tested positive for mutations such as STK11, KEAP1, or KRAS. Safety signals were consistent with the initial study analysis.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
